|
|
||||||||
Eur J Cardiothorac Surg 2006;30:722-727
© 2006 Elsevier Science NL
80 years
Division of Cardiology, University of Southern California/Keck School of Medicine, 1510 San Pablo Street, Suite 300N, Los Angeles, CA 90033, United States
Received 20 April 2006; received in revised form 24 July 2006; accepted 25 July 2006.
* Corresponding author. Tel.: +1 323 442 6130; fax: +1 323 442 6133. (Email: rpai{at}usc.edu).
| Abstract |
|---|
|
|
|---|
0.8 cm2) and age
80 years. Two hundred and seventy seven patients were identified. Complete chart reviews were performed for clinical data. Mortality data were obtained from National Death Index. Survival curves of patients who underwent AVR during the follow-up period were compared with those managed nonsurgically. Results: Patient characteristics were as follows: age 85 ± 4 years, 53% male, AV area 0.68 ± 0.16 cm2, EF 52 ± 20%, CAD 47%, diabetes 17%. Over a mean follow-up of 2.5 years, 55 (20%) had AVR and there were 175 deaths. One-year, 2-year and 5-year survival rates among patients with AVR were 87, 78 and 68% respectively, compared with 52, 40 and 22%, respectively, in those who had no AVR (p
< 0.0001). Hazard ratio for death with AVR adjusted for 19 covariates including age, EF, gender, comorbidities and pharmacotherapy was 0.38 (95% CI 0.260.66, p
< 0.0001). Conclusion: Prognosis of medically managed severe calcific AS in the elderly patients is dismal. AVR appears to improve survival of these patients and should be strongly considered in the absence of other major comorbidities.
Key Words: Aortic stenosis Aortic valve replacement Survival Echocardiography Prognosis
| 1. Introduction |
|---|
|
|
|---|
| 2. Methods |
|---|
|
|
|---|
0.8 cm2. This yielded a total of 740 patients. Of these, 277 patients were
80 years forming the study cohort. Detailed chart reviews were then performed on these patients (both alive and dead) by senior medical residents.
2.2 Clinical variables
Hypertension (HTN) was defined as blood pressure greater then 130/90 mmHg or a history of hypertension or being on medications. Diabetes was defined as having a history of or being treated with medications. Renal insufficiency was defined as serum creatinine
2 mg/dl, and coronary artery disease was defined as having a history, electrocardiographic presence of Q-waves or being on anti-anginal medications.
2.3 Pharmacological data
Pharmacotherapy at the time of echocardiography was recorded. This was broadly categorized into beta blockers, calcium channel blockers, diuretics, angiotensin-converting enzyme inhibitors, digoxin and statins.
2.4 Echocardiographic data
All patients had standard two-dimensional echocardiographic examinations. LV ejection fraction was assessed by a level-3 trained echocardiographer and entered into a database at the time of the examination. Anatomic and Doppler measurements were performed according to the recommendations of the American society of Echocardiography [15]. Aortic valve area was obtained by continuity equation.
2.5 Mortality data
The endpoint of the study was all-cause mortality. Mortality data were obtained from the National Death Index using social security numbers.
2.6 Statistical analysis
Analysis was performed using Stat View 5.01 (SAS Institute Inc., Cary, NC, USA). Characteristics of patients with and without AVR were compared using the Student's t-test for continuous variables and Chi-squared test for categorical variables. Statistical tools used for survival analysis included the KaplanMeier method, Cox regression model, propensity score analysis and sensitivity analysis as described later.
A p-value of
0.05 was considered significant.
| 3. Results |
|---|
|
|
|---|
Table 1 summarizes characteristics of elderly patients with severe AS with and without AVR. AVR group had a greater preponderance of males (57% vs 42%, p = 0.02), higher EF (56 ± 18% vs 50 ± 21%, p = 0.04), higher prevalence of hypertension (60% vs 40%, p = 0.002), higher prevalence of coronary artery disease (CAD)(62% vs 41%, p = 0.001), and greater use of cardiac medications such as aspirin (62% vs 31%, p < 0.0001) and beta blockers (44% vs 18%, p < 0.0001).
|
3.2 Survival with AVR
Of the 277 patients, 80 underwent AVR during follow-up. Survival in patients who underwent AVR was significantly better than those managed medically using KaplanMeier analysis with log-rank statistic (Fig. 1
). One-year, 2-year and 5-year survival rates among patients with AVR were 87, 78 and 68%, respectively, compared to 52, 40 and 22%, respectively in those who had no AVR (p
< 0.0001).
|
|
|
|
30% (n
= 60). Five-year survival rate was 10% in patients who did not undergo AVR compared with 52% who underwent AVR (p
= 0.003). In patients with EF
30% and a mean aortic gradient
30 mmHg (n
= 25), only two patients had underwent AVR (Fig. 4b). Survival benefit with AVR could not be assessed because of low number of patients with AVR in this subgroup, but in those patients with no AVR in this subgroup with severe AS, 1-year survival rate was dismal at 18%. Analysis of patients with CRI (n
= 32) shows that only six patients had AVR, 5-year survival rate was 12% in those who did not undergo AVR compared with 42% in those who underwent AVR (p
= 0.13) (Fig. 4c).
|
| 4. Discussion |
|---|
|
|
|---|
4.1 Benefit of AVR
Our study shows that in octogenarians with severe AS, survival is dramatically improved with AVR. AVR had significant survival benefit with 1-year, 2-year and 5-year survival rates of 87, 78 and 68%, respectively, compared with 52, 40 and 22%, respectively, in those who had no AVR (p
< 0.0001). On multivariate analysis, lower ejection fraction and, renal insufficiency were predictors of increased mortality. Old age and smaller aortic valve area showed a trend towards increased mortality, which was not statistically significant. AVR was a strong independent predictor of improved survival. There is a paucity of studies in the literature comparing survival with and without AVR for severe aortic stenosis in those aged
80 years. Gilbert et al. [11] reported that 103 patients from a single center in the UK with severe AS underwent AVR. Median age in this study was 82 years. The 50% actuarial survival in this study was 62 months. Early postoperative mortality was related to increasing age, renal impairment and peripheral vascular disease. Patients who survived the surgery had good long-term prognosis. One-year, 2-year and 5-year survival rates were 78, 75 and 58%, respectively, in all patients undergoing AVR (by examining the published KaplanMeier survival curves). Bouma et al. [14] evaluated the decision-making process leading to medical or surgical treatment for aortic stenosis in elderly patients. There were 67 patients aged
80 years. This study showed 3-year survival rates of 80% in the surgical group compared with 49% in the non-AVR group. Our study is the largest study evaluating the survival pattern with and without AVR in patients aged 80 and more with severe AS and shows similar survival patterns.
4.2 Outcomes after AVR in patients aged 80 and more
There are studies reporting good outcomes after AVR in the elderly. Gehlot et al. [8] studied 322 patients with a mean age of 82.2 years who underwent AVR. On multivariate analysis, the most important independent predictors of mortality included female gender, renal impairment, EF < 35%, bypass grafting and chronic obstructive pulmonary disease. Age and year of operation did not influence mortality. Five-year survival rates for all patients and for operative survivors were 60.2 ± 3.2% and 70.3 ± 3.4%. Asimakopoulos et al. [10] reported on data collected from 1100 patients >80 years undergoing AVR from the UK Heart Valve Registry. Actuarial survival rates were 89, 79, 69% and 46% at 1, 3, 5 and 8 years, respectively. Survival in the operated patients in our series was practically identical to this. Sundt et al. [17] retrospectively evaluated 133 patients between the age of 80 and 91 years undergoing AVR. Actuarial survival rates at 1 and 5 years were 80 and 55%, respectively. Urgent or emergent surgery, aortic insufficiency, perioperative stroke or renal dysfunction were significant risk factors for operative death by multivariate analysis.
4.3 Strengths of our study
Ours is the largest study addressing this issue, and our patients are well characterized in terms of clinical, pharmacologic and echocardiographic data. We used robust statistical tools like propensity score analysis and sensitivity analysis in addition to the standard KaplanMeier analysis. Propensity score analysis was used to correct covariate imbalances. Modeling based on propensity scores is estimated to remove up to 90% of inherent bias of a retrospective study [18]. Propensity score analysis reveals strong survival benefit with AVR in octogenarians with severe AS. As there is a nonproportionate mortality hazard during the first 30 days, sensitivity analysis was carried out to serially eliminate these initial observations and determine the survival benefit of AVR. By serial elimination of observations before 30 days, 90 days, 1 year and 2 years, AVR continues to show a very strong survival benefit.
4.4 Limitations
This is a retrospective, observational study and hence is prone to inherent bias of a retrospective study. Though various statistical tools were used to attempt to remove effect of selection of bias on survival, a prospective randomized study is the only way to answer this clinical question in unequivocal terms.
4.5 Conclusions
Our study shows that medically managed octogenarians with severe aortic stenosis have a dismal prognosis, and AVR improves survival. Hence, strong consideration should be given for aortic valve replacement in octogenarians in the absence of serious comorbidities.
| Acknowledgments |
|---|
| Footnotes |
|---|
Presented at the 78th Annual Scientific Sessions of the American Heart Association, Dallas, Texas, USA, November 2005. | References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
J. G. Webb, L. Altwegg, R. H. Boone, A. Cheung, J. Ye, S. Lichtenstein, M. Lee, J. B. Masson, C. Thompson, R. Moss, et al. Transcatheter Aortic Valve Implantation: Impact on Clinical and Valve-Related Outcomes Circulation, June 16, 2009; 119(23): 3009 - 3016. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. W.A. van Geldorp, M. van Gameren, A. P. Kappetein, B. Arabkhani, L. E. de Groot-de Laat, J. J.M. Takkenberg, and A. J.J.C. Bogers Therapeutic decisions for patients with symptomatic severe aortic stenosis: room for improvement? Eur. J. Cardiothorac. Surg., June 1, 2009; 35(6): 953 - 957. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. L. Hannan, Z. Samadashvili, S. J. Lahey, C. R. Smith, A. T. Culliford, R. S.D. Higgins, J. P. Gold, and R. H. Jones Aortic Valve Replacement for Patients With Severe Aortic Stenosis: Risk Factors and Their Impact on 30-Month Mortality. Ann. Thorac. Surg., June 1, 2009; 87(6): 1741 - 1749. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Leontyev, T. Walther, M. A. Borger, S. Lehmann, A. K. Funkat, A. Rastan, J. Kempfert, V. Falk, and F. W. Mohr Aortic valve replacement in octogenarians: utility of risk stratification with EuroSCORE. Ann. Thorac. Surg., May 1, 2009; 87(5): 1440 - 1445. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Balaras, K.S. Cha, B. P. Griffith, and J. S. Gammie Treatment of aortic stenosis with aortic valve bypass (apicoaortic conduit) surgery: an assessment using computational modeling. J. Thorac. Cardiovasc. Surg., March 1, 2009; 137(3): 680 - 687. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Zingone, G. Gatti, E. Rauber, P. Tiziani, L. Dreas, A. Pappalardo, B. Benussi, and A. Spina Early and Late Outcomes of Cardiac Surgery in Octogenarians Ann. Thorac. Surg., January 1, 2009; 87(1): 71 - 78. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. G. Pai, P. Varadarajan, and A. Razzouk Survival Benefit of Aortic Valve Replacement in Patients With Severe Aortic Stenosis With Low Ejection Fraction And Low Gradient With Normal Ejection Fraction Ann. Thorac. Surg., December 1, 2008; 86(6): 1781 - 1789. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Kempfert, T. Walther, M. A. Borger, S. Lehmann, J. Blumenstein, J. Fassl, G. Schuler, and F.-W. Mohr Minimally Invasive Off-Pump Aortic Valve Implantation: The Surgical Safety Net Ann. Thorac. Surg., November 1, 2008; 86(5): 1665 - 1668. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Gammie, L. S. Krowsoski, J. M. Brown, P. N. Odonkor, C. A. Young, M. J. Santos, J. S. Gottdiener, and B. P. Griffith Aortic Valve Bypass Surgery: Midterm Clinical Outcomes in a High-Risk Aortic Stenosis Population Circulation, September 30, 2008; 118(14): 1460 - 1466. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. de Vincentiis, A. B. Kunkl, S. Trimarchi, P. Gagliardotto, A. Frigiola, L. Menicanti, and M. Di Donato Aortic Valve Replacement in Octogenarians: Is Biologic Valve the Unique Solution? Ann. Thorac. Surg., April 1, 2008; 85(4): 1296 - 1301. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. S. Bach, N. Cimino, and G. M. Deeb Unoperated Patients With Severe Aortic Stenosis J. Am. Coll. Cardiol., November 13, 2007; 50(20): 2018 - 2019. [Full Text] [PDF] |
||||
![]() |
R. G. Pai, P. Varadarajan, N. Kapoor, and R. C. Bansal Aortic Valve Replacement Improves Survival in Severe Aortic Stenosis Associated With Severe Pulmonary Hypertension Ann. Thorac. Surg., July 1, 2007; 84(1): 80 - 85. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |